Meeting
2023 ASCO Annual Meeting
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.
Authors
Sarah M. Nielsen
Invitae, San Francisco, CA
Sarah M. Nielsen , Brandie Heald , Joanne YY Ngeow , Yanin Chavarri Guerra , Emily M. Russell , Edward D. Esplin , Daniel Esteban Pineda Alvarez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10590)
DOI
10.1200/JCO.2023.41.16_suppl.10590
Abstract #
10590
Poster Bd #
223
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2022 ASCO Genitourinary Cancers Symposium
Identification of homologous recombination and repair (HRR) deficiency using circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC).
First Author: Leslie A. Bucheit